trending Market Intelligence /marketintelligence/en/news-insights/trending/6bz7pf1ewudbqcmfhx4gua2 content esgSubNav
In This List

Avinger secures US FDA clearance for device to treat blocked arteries

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Avinger secures US FDA clearance for device to treat blocked arteries

The U.S. Food and Drug Administration granted 510(k) clearance to Avinger Inc.'s Pantheris lumivascular atherectomy system, a surgical device for treating peripheral artery disease.

Peripheral artery disease, or PAD, is characterized by blockage or narrowing of arteries. It mostly affects the legs but also affects the arms, stomach and head, leading to reduced blood flow that can result in severe pain and limit physical mobility.

Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel.

Avinger said its next-generation Pantheris lumivascular atherectomy system is the first-ever image-guided atherectomy device for treating PAD.

The Redwood City, Calif.-based medical device-maker said PAD is projected to affect more than 21 million people in the U.S. alone by 2020.